Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis

The tubulin polymerization and Src kinase inhibitor tirbanibulin was superior to placebo ointment in clearing actinic keratoses on the face and scalp at 2 months. As is typical of the disorder, lesions recurred in 47% of patients at 1 year. Adverse events were related to local irritation.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-02, Vol.384 (6), p.512-520
Hauptverfasser:	Blauvelt, Andrew, Kempers, Steven, Lain, Edward, Schlesinger, Todd, Tyring, Stephen, Forman, Seth, Ablon, Glynis, Martin, George, Wang, Hui, Cutler, David L, Fang, Jane, Kwan, Min-Fun R
Format:	Artikel
Sprache:	eng
Schlagworte:	Acetamides - adverse effects Acetamides - therapeutic use Administration, Topical Adverse events Aged Cell division Clinical trials Double-Blind Method Enzyme inhibitors Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Erythema Face - pathology Female Humans Kaplan-Meier Estimate Keratosis Keratosis, Actinic - drug therapy Lesions Male Middle Aged Morpholines - adverse effects Morpholines - therapeutic use Ointments - therapeutic use Patients Placebos Polymerization - drug effects Pruritus Pyridines - adverse effects Pyridines - therapeutic use Scalp Scalp - pathology Skin - pathology Squamous cell carcinoma Statistical analysis Tubulin Tubulin - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The tubulin polymerization and Src kinase inhibitor tirbanibulin was superior to placebo ointment in clearing actinic keratoses on the face and scalp at 2 months. As is typical of the disorder, lesions recurred in 47% of patients at 1 year. Adverse events were related to local irritation.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2024040